First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Neoplasms
DRUG: GSK4381562|DRUG: Dostarlimab|DRUG: Belrestotug|DRUG: Nelistotug|DRUG: GSK5764227
Arms A, B, C, I: Number of Participants with dose-limiting toxicities (DLTs), Up to 21 days|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Up to 27 months
Number of Participants With Clinically Significant Changes in Laboratory Parameters, Electrocardiogram (ECG) and Vital Signs, Up to 24 months|Number of Participants With Dose Reductions or Delays, Up to 24 months|Number of Participants With Withdrawals due to AEs, Number of participants with adverse events leading to permanent discontinuation of study treatment or withdrawal from study by overall frequency will be assessed., Up to 27 months|Overall Response Rate (ORR), Overall response rate will be calculated as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. It is defined as the percentage of participants with a best overall confirmed complete response (CR) or partial response (PR) at any time as per disease-specific criteria., Up to 24 months|Number of Participants With Positive Antidrug Antibodies (ADA) to GSK4381562, Up to 27 months|Titres of ADA to GSK4381562, Up to 27 months|Number of Participants With Positive ADA to Dostarlimab, Up to 27 months|Titers of ADA to Dostarlimab, Up to 27 months|Number of Participants With Positive ADA to belrestotug, Up to 27 months|Titers of ADA to belrestotug, Up to 27 months|Number of Participants With Positive ADA to nelistotug, Up to 27 months|Titers of ADA to nelistotug, Up to 27 months|Number of Participants With Positive ADA to GSK5764227, Up to 27 months|Titers of ADA to GSK5764227, Up to 27 months|Serum Concentrations of GSK4381562, Up to 4 months|Serum Concentrations of dostarlimab, Up to 4 months|Serum Concentrations of belrestotug, Up to 4 months|Serum Concentrations of nelistotug, Up to 4 months|Serum Concentrations of GSK5764227, Up to 4 months|Maximum Observed Plasma Concentration (Cmax) of GSK4381562 Monotherapy, Up to 27 months|Cmax of GSK4381562 in Combination With Dostarlimab, Up to 27 months|Cmax of GSK4381562 in Combination With dostarlimab and belrestotug, Up to 27 months|Cmax following administration of dostarlimab with belrestotug, Up to 27 months|Minimum Observed Plasma Concentration (Cmin) of GSK4381562 Monotherapy, Up to 27 months|Cmin of GSK4381562 in Combination With Dostarlimab, Up to 27 months|Cmin of GSK4381562 in Combination With dostarlimab and belrestotug, Up to 27 months|Cmin following administration of dostarlimab with belrestotug, Up to 27 months|Area Under the Plasma Concentration Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) of GSK4381562, Up to 27 months|AUC(0-t) of GSK4381562 in Combination With Dostarlimab, Up to 27 months|AUC(0-t) of GSK4381562 in Combination With dostarlimab and belrestotug, Up to 27 months|AUC(0-t) following administration of dostarlimab with belrestotug, Up to 27 months|AUC From Time Zero to Infinity (AUC[0-infinity]) of Single Dosing of GSK4381562, Up to 27 months|AUC(0-infinity) of Single Dosing of GSK4381562 in Combination with Dostarlimab, Up to 27 months|AUC(0-infinity) of Single Dosing of GSK4381562 in Combination With dostarlimab and belrestotug, Up to 27 months|AUC(0-infinity) following administration of dostarlimab with belrestotug, Up to 27 months|Cmax of dostarlimab in Combination With GSK4381562, Up to 27 months|Cmax of dostarlimab in combination with GSK5764227, Up to 27 months|Cmax of dostarlimab in combination with GSK4381562 followed by belrestotug, Up to 27 months|Cmax of dostarlimab in combination with belrestotug, Up to 27 months|Cmax of dostarlimab in combination with belrestotug and GSK4381562, Up to 27 months|Cmax of dostarlimab in combination with belrestotug and nelistotug, Up to 27 months|China cohort: Cmax of dostarlimab monotherapy, Up to 27 months|China cohort: Cmax of dostarlimab in combination with belrestotug, Up to 27 months|Cmin of dostarlimab in Combination With GSK4381562, Up to 27 months|Cmin of dostarlimab in combination with GSK5764227, Up to 27 months|Cmin of dostarlimab in combination with GSK4381562 followed by belrestotug, Up to 27 months|Cmin of dostarlimab in combination with belrestotug, Up to 27 months|Cmin of dostarlimab in combination with belrestotug and GSK4381562, Up to 27 months|Cmin of dostarlimab in combination with belrestotug and nelistotug, Up to 27 months|China cohort: Cmin of dostarlimab monotherapy, Up to 27 months|China cohort: Cmin of dostarlimab in combination with belrestotug, Up to 27 months|AUC(0-t) of dostarlimab in Combination With GSK4381562, Up to 27 months|AUC(0-t) of dostarlimab in combination with GSK5764227, Up to 27 months|AUC(0-t) of dostarlimab in combination with GSK4381562 followed by belrestotug, Up to 27 months|AUC(0-t) of dostarlimab in combination with belrestotug, Up to 27 months|AUC(0-t) of dostarlimab in combination with belrestotug and GSK4381562, Up to 27 months|AUC(0-t) of dostarlimab in combination with belrestotug and nelistotug, Up to 27 months|China cohort: AUC(0-t) of dostarlimab monotherapy, Up to 27 months|China cohort: AUC(0-t) of dostarlimab in combination with belrestotug, Up to 27 months|AUC(0-infinity) of dostarlimab in Combination With GSK4381562, Up to 27 months|AUC(0-infinity) of dostarlimab in combination with GSK5764227, Up to 27 months|AUC(0-infinity) of dostarlimab in combination with GSK4381562 followed by belrestotug, Up to 27 months|AUC(0-infinity) of dostarlimab in combination with belrestotug, Up to 27 months|AUC(0-infinity) of dostarlimab in combination with belrestotug and GSK4381562, Up to 27 months|AUC(0-infinity) of dostarlimab in combination with belrestotug and nelistotug, Up to 27 months|China cohort: AUC(0-infinity) of dostarlimab monotherapy, Up to 27 months|China cohort: AUC(0-infinity) of dostarlimab in combination with belrestotug, Up to 27 months|Mean terminal half-life (t1/2) of dostarlimab in Combination With GSK4381562, Up to 27 months|Mean terminal half-life (t1/2) of dostarlimab in combination with GSK5764227, Up to 27 months|China cohort: t1/2 of dostarlimab monotherapy, Up to 27 months|China cohort: t1/2 of dostarlimab in combination with belrestotug, Up to 27 months|Cmax of belrestotug in combination with dostarlimab followed by GSK4381562, Up to 27 months|Cmax of belrestotug in combination with dostarlimab, Up to 27 months|Cmax of belrestotug in combination with dostarlimab and GSK4381562, Up to 27 months|Cmax of belrestotug in combination with dostarlimab and nelistotug, Up to 27 months|China cohort: Cmax of belrestotug in combination with dostarlimab, Up to 27 months|Cmin of belrestotug in combination with dostarlimab followed by GSK4381562, Up to 27 months|Cmin of belrestotug in combination with dostarlimab, Up to 27 months|Cmin of belrestotug in combination with dostarlimab and GSK4381562, Up to 27 months|Cmin of belrestotug in combination with dostarlimab and nelistotug, Up to 27 months|China cohort: Cmin of belrestotug in combination with dostarlimab, Up to 27 months|AUC (0-t) of belrestotug in combination with dostarlimab followed by GSK4381562, Up to 27 months|AUC (0-t) of belrestotug in combination with dostarlimab, Up to 27 months|AUC (0-t) of belrestotug in combination with dostarlimab and GSK4381562, Up to 27 months|AUC (0-t) of belrestotug in combination with dostarlimab and nelistotug, Up to 27 months|China cohort: AUC (0-t) of belrestotug in combination with dostarlimab, Up to 27 months|AUC (0-infinity) of belrestotug in combination with dostarlimab followed by GSK4381562, Up to 27 months|AUC (0- infinity) of belrestotug in combination with dostarlimab, Up to 27 months|AUC (0- infinity) of belrestotug in combination with dostarlimab and GSK4381562, Up to 27 months|AUC (0- infinity) of belrestotug in combination with dostarlimab and nelistotug, Up to 27 months|China cohort: AUC (0- infinity) of belrestotug in combination with dostarlimab, Up to 27 months|China cohort: t1/2 of belrestotug in combination with dostarlimab, Up to 27 months|Cmax of nelistotug in combination with dostarlimab and belrestotug, Up to 27 months|Cmin of nelistotug in combination with dostarlimab and belrestotug, Up to 27 months|AUC (0-t) of nelistotug in combination with dostarlimab and belrestotug, Up to 27 months|AUC (0-infinity) of nelistotug in combination with dostarlimab and belrestotug, Up to 27 months|Cmax of GSK5764227 in combination with dostarlimab, Up to 27 months|Cmin of GSK5764227 in combination with dostarlimab, Up to 27 months|AUC (0-t) of GSK5764227 conjugated antibody (Ab) in combination with dostarlimab, Up to 27 months|AUC (0-t) of GSK5764227 small molecule toxin in combination with dostarlimab, Up to 27 months|AUC (0-infinity) of GSK5764227 conjugated Ab in combination with dostarlimab, Up to 27 months|AUC (0-infinity) of GSK5764227 small molecule toxin in combination with dostarlimab, Up to 27 months
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.